BioSpace News Archive

Illuminare Biotechnologies, a clinical-stage biotechnology company, announced that its novel nerve imaging agent, Illuminare-1, has been granted Fast Track Designation by the US Food and Drug Administration (FDA). Illuminare-1 is a small molecule, myelin binding agent, the company is developing as a surgical adjunct to improve the visualization Investigational Fluorophore

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021.

MD Anderson’s International Radiation Treatment Center Expands Offering with Selection of ViewRay’s MRIdian System for Adaptive Radiotherapy

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron”) today announced that it has sold $150 million of senior unsecured convertible promissory notes (the “Notes”) in a private placement transaction.

Goal to develop regulatory-approved software products and services based on AI-generated insights from Quest’s digital pathology diagnostic data

- Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care) - Patient enrollment on track to begin this quarter - Interim data expected in the second half of 2022

Seegrid Corporation, the leader in autonomous mobile robots (AMRs) for material handling, announced the formation of Blue Labs, a research and development group committed to furthering the company’s strong technical advantage.

Innovative MedTech, Inc. (the “Company”) (OTC: IMTH), a provider of health and wellness services, announced today the appointment of Monique M. Pizzute as the Director of Franchise Support for the Company’s subsidiary, SarahCare Adult Day Services.

SafeRX Pharmaceuticals Inc. , a company developing an ARO (Alcohol Resistant Opioid) platform for preventing opioid/alcohol-related deaths, announced today that it is launching an equity crowdfunding campaign via Regulation CF to raise funds for its patented solution to this dimension of the national health crisis.

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced today that the U.S. Food and Drug Administration (FDA) posted briefing documents for the May 27, 2021 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)